ArticleFrontiers in psychiatry2025
Higher clozapine concentration-to-dose ratios at week 1 after initiation are associated with increased risk of clozapine-associated fever in Japanese patients with schizophrenia.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The clinical use of clozapine in the treatment of schizophrenia is sometimes halted due to its inflammatory side effects. However, no method has been established for preemptively identifying patients who are at high risk for these events. Therefore, in this study, we assessed whether the blood clozapine concentration-to-dose ratio (C/D) on day 8 after initiation could predict the risk of clozapine-associated fever. Method: Patients whose blood levels of clozapine were measured on day 8 after initiation were retrospectively investigated. The C/D ratio on day 8 was compared between patients who had fever after day 8 and those who did not. Results: A total of 43 patients were included in the study. The range of C/D ratios on day 8 was from 0.35-4.0, with a median of 1.65. Patients with fever had significantly higher C/D ratios on day 8 than those without fever (2.33 vs. 1.47; P < 0.005). Conclusion: Measuring blood clozapine levels on day 8 may help to better estimate the risk of clozapine-associated fever in patients with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.